Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Merck Sharp & Dohme LLC
Age
18–49
Sex
ALL
Healthy volunteers
Accepted
You may be eligible if
Has underlying chronic conditions but assessed to be stable as per investigator
Has ability to complete electronic Vaccine Report Card (eVRC) data collection without assistance as per investigator
You may not be if
Has a history of invasive pneumococcal disease (IPD) or other culture-positive pneumococcal disease ≤3 years before Visit 1 (Day 1)
Has a known or suspected congenital immunodeficiency, functional or anatomic asplenia, or history of autoimmune disease
Has a coagulation disorder contraindicating intramuscular vaccination
Has a recent illness with fever
Has a known malignancy that is progressing or has required active treatment \<3 years before enrollment
Is expected to receive any pneumococcal vaccine during the study outside of the protocol
Has received systemic corticosteroids for ≥14 consecutive days and has not completed treatment ≥14 days before receipt of study vaccine
Is currently receiving immunosuppressive therapy, including chemotherapeutic agents or other immunotherapies/immunomodulators used to treat cancer or other conditions, and interventions associated with organ or bone marrow transplantation, or autoimmune disease
Has received any non-live vaccine ≤14 days before receipt of study vaccine or is scheduled to receive any non-live vaccine ≤30 days after receipt of study vaccine
Has received any live vaccine ≤30 days before receipt of study vaccine or is scheduled to receive any live vaccine ≤30 days after receipt of study vaccine
Has received a blood transfusion or blood products, including immunoglobulins ≤6 months before receipt of study vaccine or is scheduled to receive a blood transfusion or blood product ≤30 days after receipt of study vaccine
Clareo Health | A Study to Evaluate the Safety, Tolerability, Immunogenicity, and Lot Consistency of V116 in Adults 18 to 49 Years of Age (V116-004, STRIDE-4)
